These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

754 related items for PubMed ID: 23494648

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    Agostini S, Mancuso R, Citterio LA, Caputo D, Oreni L, Nuzzi R, Pasanisi MB, Rovaris M, Clerici M.
    Neurobiol Dis; 2024 Oct 01; 200():106648. PubMed ID: 39181188
    [Abstract] [Full Text] [Related]

  • 3. Differential microRNA expression in blood in multiple sclerosis.
    Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F.
    Mult Scler; 2013 Dec 01; 19(14):1849-57. PubMed ID: 23773985
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Vistbakka J, Elovaara I, Lehtimäki T, Hagman S.
    Mult Scler; 2017 Mar 01; 23(3):403-412. PubMed ID: 27246141
    [Abstract] [Full Text] [Related]

  • 6. Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases.
    Sharaf-Eldin WE, Kishk NA, Gad YZ, Hassan H, Ali MAM, Zaki MS, Mohamed MR, Essawi ML.
    J Neurol Sci; 2017 Dec 15; 383():188-198. PubMed ID: 29246612
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.
    Keller A, Leidinger P, Steinmeyer F, Stähler C, Franke A, Hemmrich-Stanisak G, Kappel A, Wright I, Dörr J, Paul F, Diem R, Tocariu-Krick B, Meder B, Backes C, Meese E, Ruprecht K.
    Mult Scler; 2014 Mar 15; 20(3):295-303. PubMed ID: 23836875
    [Abstract] [Full Text] [Related]

  • 8. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 15; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 9. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.
    Yang G, Yang L, Wang W, Wang J, Wang J, Xu Z.
    Gene; 2015 May 10; 562(1):138-44. PubMed ID: 25725128
    [Abstract] [Full Text] [Related]

  • 10. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M, Vaneckova M, Krasensky J, Danes J, Havrdova E, Hrebikova T, Seidl Z.
    Neuro Endocrinol Lett; 2008 Aug 10; 29(4):461-6. PubMed ID: 18766142
    [Abstract] [Full Text] [Related]

  • 11. Analysis of potential microRNA biomarkers for multiple sclerosis.
    Al-Temaimi R, Alshammari N, Alroughani R.
    Exp Mol Pathol; 2024 Jun 10; 137():104903. PubMed ID: 38772208
    [Abstract] [Full Text] [Related]

  • 12. Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis.
    Takahashi I, Hama Y, Matsushima M, Hirotani M, Kano T, Hohzen H, Yabe I, Utsumi J, Sasaki H.
    Mol Brain; 2015 Oct 24; 8(1):67. PubMed ID: 26497046
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study.
    Sağır F, Ersoy Tunalı N, Tombul T, Koral G, Çırak S, Yılmaz V, Türkoğlu R, Tüzün E.
    Genet Test Mol Biomarkers; 2021 Nov 24; 25(11):720-726. PubMed ID: 34788141
    [Abstract] [Full Text] [Related]

  • 15. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
    Kacperska MJ, Jastrzebski K, Tomasik B, Walenczak J, Konarska-Krol M, Glabinski A.
    J Mol Neurosci; 2015 May 24; 56(1):154-63. PubMed ID: 25487315
    [Abstract] [Full Text] [Related]

  • 16. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP.
    Cytokine; 2008 Oct 24; 44(1):22-5. PubMed ID: 18793860
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H, Yinshan Zhao, Devonshire V.
    Mult Scler; 2008 Apr 24; 14(3):314-24. PubMed ID: 18208898
    [Abstract] [Full Text] [Related]

  • 20. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.